<GlossaryTerm id="CDR0000801467"><TermName>pemigatinib</TermName><TermPronunciation>(PEH-mih-GA-tih-nib)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat adults with certain types of cholangiocarcinoma (bile duct cancer), myeloid cancer, or lymphoid cancer that have certain changes in the structure of the <GeneName>FGFR1</GeneName> gene or <GeneName>FGFR2</GeneName> gene. It is also being studied in the treatment of other types of cancer. Pemigatinib blocks a protein called FGFR, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called Pemazyre.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000802704" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;pemigatinib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000802705" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;pemigatinib&quot;" language="es" id="_4"/><SpanishTermName>pemigatinib</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para el tratamiento de adultos con determinados tipos de colangiocarcinoma (cáncer de vías biliares), cáncer mieloide o cáncer linfoide que presenta ciertos cambios en la estructura del gen <GeneName>FGFR1</GeneName> o del gen <GeneName>FGFR2</GeneName>. También está en estudio para el tratamiento de otros tipos de cáncer. El pemigatinib bloquea una proteína llamada FGFR, lo que quizás ayude a impedir que las células cancerosas se multipliquen y tal vez las destruya. Es un tipo de inhibidor de tirosina–cinasas. También se llama Pemazyre.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2020-04-22</DateFirstPublished><DateLastModified>2022-08-31</DateLastModified><RelatedInformation><RelatedDrugSummaryRef UseWith="en" href="CDR0000801476" url="/about-cancer/treatment/drugs/pemigatinib">Pemigatinib</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
